Treatment of pediatric-onset relapsing-remitting multiple sclerosis with high-efficacy therapy reduces the risk for transition across disability states, according to a study published in the May issue ...
Please provide your email address to receive an email when new articles are posted on . Results were presented at ASCO Annual Meeting. “Overall, the single agent odronextamab (Regeneron ...
Starting high-efficacy monoclonal antibody therapy during childhood reduced long-term disability in pediatric-onset multiple sclerosis (MS), registry data suggested. Among 282 patients with ...
As the standard of care for relapsing-remitting multiple sclerosis (RRMS), high-efficacy therapy (HET) should be started as early as possible after diagnosis. However, there are adverse effects, ...
A phase 2b clinical trial demonstrates the potential of zasocitinib in achieving biologic-level efficacy with minimal adverse effects. A recent phase 2b clinical trial of zasocitinib, a selective oral ...
In a rapidly expanding therapeutic landscape, the American Gastroenterological Association (AGA) has issued updated practice guidelines for the pharmacological management of moderate to severe ...
GSK will continue evaluating long-term data and conducting real-world studies for its shingles vaccine efficacy, immunogenicity, and safety. GSK's gepotidacin was non-inferior to a leading combination ...
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results